民主党将调查特朗普政府的最惠国药品定价协议
STAT+: Democrats take new step toward investigating Trump’s drug pricing deals
入选的民主党关键委员会主席近日要求制药公司披露与特朗普政府签订的最惠国药品定价协议详情,这些协议预计将成为民主党在明年掌握多数后的首要监管重点。已有更多公司与特朗普政府签署此类协议,国会消息人士透露,近期已向27家公司发出新的披露要求。
WASHINGTON — The incoming Democratic chairs of key committees have taken a new step toward investigating the most-favored nation drug pricing agreements between drugmakers and the Trump administration.
The drug pricing deals are expected to be a top health care oversight priority for Democrats once they take the majority in January. Earlier this year, the top Democrats on the Senate Finance Committee and the House Energy and Commerce, Ways and Means, and Education and Labor committees requested that companies disclose the details of the deals they struck to tie Medicaid drug prices to levels in peer countries.
Since then, additional companies have signed agreements with the Trump administration. A new round of letters were recently sent to all 27 companies, according to a congressional source familiar with the letters. Endpoints News first reported the new requests.
STAT+ Exclusive Story
Already have an account? Log in

This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
来源:STAT 主站 · statnews.com